Fate Therapeutics Raises $30 Million
Fate Therapeutics, a La Jolla, Calif.-based stem cell biotech company focused on cell fate control, has raised $30 million in Series B funding. OVP Venture Partners led the round, and was joined by fellow return backers ARCH Venture Partners, Polaris Venture Partners and Venrock. The company previously raised $12 million.
16 November 2009•4 mins read
